Mother Died in Nine Months — Now He’s Next?

Red attention stamp on white background — IMPORTANT NEWS ALERT

A researcher who studied gene regulation his entire career discovered he carried the same rare genetic mutation that killed his mother and is now racing against time in an experimental drug trial to save his own life.

Story Snapshot

Jeff Vierstra, a gene regulation researcher, carries the FUS mutation linked to one of ALS’s most aggressive forms, which killed his mother in nine months
A chance conversation at a scientific conference connected him with Dr. Neil Shneider, whose preclinical research showed an experimental drug could silence the FUS gene in mice
Jeff enrolled as a presymptomatic patient in summer 2020, while his two sisters with active symptoms also joined the trial through an FDA expanded access program
Autopsy findings showed the drug achieved its biological target by reducing toxic protein levels, even as clinical outcomes remained mixed and unpredictable

When a Chance Encounter Changes Everything

Jeff Vierstra’s genealogical records stretched back generations, each entry telling the same devastating story. Multiple family members had died in their thirties and forties from a disease that progressively paralyzed their bodies while leaving their minds intact.

When Jeff finally learned he carried the FUS gene mutation responsible for this pattern, the weight of that inheritance became inescapable. His mother had survived only nine months after her first symptoms appeared.

His oldest sister Erin developed neuromuscular symptoms. His third sibling Leigh received the same diagnosis. The family curse now had a molecular explanation, but no cure.

Scientist whose mother and sisters died of ALS complications hopes experimental treatment will save his life https://t.co/9PQCDmuZYL

— CBS News (@CBSNews) April 5, 2026

Then came the scientific conference in Barbados. During conversations with fellow researchers, Jeff revealed his family history to Dr. Hemali Phatnani, who connected him with Dr. Neil Shneider at Columbia University.

Shneider had spent years conducting preclinical research demonstrating that an experimental drug created by Ionis Pharmaceuticals could silence the FUS gene in mice, reducing toxic protein levels in the brain and spinal cord while delaying motor neuron damage.

What began as casual academic discussion became a lifeline. By summer 2020, Jeff, Erin, and Leigh had enrolled in an investigator-initiated expanded access program—a specialized FDA pathway designed for rare genetic conditions where standard clinical trials are impractical.

The Ultra-Rare Disease Nobody Wants to Study

FUS ALS represents one of the most aggressive forms of amyotrophic lateral sclerosis, striking teenagers and young adults with devastating speed. While five to ten percent of all ALS cases are hereditary, FUS mutations account for an ultra-rare subset of those cases.

The disease attacks motor neurons in the spinal cord and brain, causing progressive muscle weakness and paralysis while cognitive and sensory functions remain cruelly intact. Patients watch themselves disappear into their own bodies. For Jeff’s family, this wasn’t abstract medical literature. It was lived experience across generations.

Dr. Shneider’s characterization of FUS ALS captured the urgency driving the research: “one of the most aggressive forms of the disease, striking teens and young adults and often killing within months of symptom onset.” Jeff’s case presented a unique opportunity.

Unlike his sisters, who were already symptomatic when they enrolled, electrical muscle activity tests suggested Jeff would likely develop symptoms soon despite appearing healthy. This made him an ideal candidate for presymptomatic intervention—a preventive approach rarely possible in neurodegenerative diseases. His motivation was straightforward: improve his odds of survival.

When Biology Works But Patients Still Decline

The outcomes defied simple interpretation. The first trial patient, a young woman with rapidly advancing disease, died approximately one year after starting treatment. Her death initially appeared to validate the skeptics. But then came the autopsy.

Pathologists discovered the drug had markedly reduced toxic FUS protein levels in her brain with no apparent side effects. The biological mechanism worked. The drug silenced the gene as intended. Yet the patient still died. This contradiction—efficacy at the molecular level coupled with clinical decline—captured the brutal uncertainty of rare disease treatment.

Erin received the experimental treatment for approximately three years but continued to slowly decline and eventually passed away. Leigh survived four years of treatment before dying from an unrelated head injury, meaning the drug itself had not caused her death. Yet neither sister experienced the dramatic symptom reversal that hope had whispered might be possible.

Jeff remained enrolled in the program, continuing treatment as a presymptomatic patient whose future remained unknowable.

He had described the experience as devastating, particularly witnessing ALS “rob my sisters and mom’s lives,” but he also acknowledged the fortunate convergence of circumstances that had given him access to a targeted treatment most patients with rare genetic diseases never receive.

The Precision Medicine Gamble

Jeff’s case illustrated both the promise and the limitations of precision medicine in neurodegenerative diseases. The drug worked at the molecular level, validating the therapeutic approach even when clinical outcomes remained mixed. This distinction mattered enormously. It meant future iterations of the treatment might prove more effective.

It meant other genetic ALS subtypes could potentially be targeted with similar antisense oligonucleotide technology. It meant rare disease patients might eventually access investigator-initiated expanded access programs rather than waiting for large-scale clinical trials that may never materialize for ultra-rare conditions.

The expanded access program model itself represented a shift in how medicine approaches genetic rarity. Rather than requiring thousands of patients for statistical significance, researchers could now provide access to promising therapies for extremely small patient populations.

Jeff’s family became part of a larger story about how genetic understanding could be translated into personalized treatment opportunities. Whether that translation would ultimately save his life remained uncertain. But the possibility itself—born from a chance conversation and sustained by decades of research—represented a distinctly modern form of hope.